Short Interest in BrainsWay Ltd. (NASDAQ:BWAY) Increases By 68.0%

BrainsWay Ltd. (NASDAQ:BWAY) saw a large growth in short interest in January. As of January 31st, there was short interest totalling 63,000 shares, a growth of 68.0% from the January 15th total of 37,500 shares. Based on an average trading volume of 67,300 shares, the short-interest ratio is presently 0.9 days.

BrainsWay Stock Performance

NASDAQ:BWAY traded up $0.28 during mid-day trading on Friday, hitting $11.30. The stock had a trading volume of 109,144 shares, compared to its average volume of 56,067. BrainsWay has a twelve month low of $4.61 and a twelve month high of $11.50. The stock has a market cap of $212.62 million, a price-to-earnings ratio of 113.01 and a beta of 1.25. The company’s 50 day simple moving average is $10.00 and its 200 day simple moving average is $9.21.

BrainsWay (NASDAQ:BWAY) last issued its earnings results on Tuesday, November 12th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03. BrainsWay had a net margin of 3.88% and a return on equity of 3.52%. The business had revenue of $10.50 million during the quarter, compared to the consensus estimate of $10.07 million. During the same period last year, the business posted ($0.01) EPS. As a group, equities analysts forecast that BrainsWay will post 0.08 earnings per share for the current year.

Institutional Investors Weigh In On BrainsWay

Several hedge funds have recently bought and sold shares of the stock. MYDA Advisors LLC lifted its position in BrainsWay by 100.2% during the fourth quarter. MYDA Advisors LLC now owns 120,100 shares of the company’s stock worth $1,133,000 after acquiring an additional 60,100 shares during the last quarter. Zuckerman Investment Group LLC lifted its position in BrainsWay by 346.4% during the fourth quarter. Zuckerman Investment Group LLC now owns 67,000 shares of the company’s stock worth $667,000 after acquiring an additional 51,991 shares during the last quarter. Phoenix Financial Ltd. lifted its position in BrainsWay by 100.8% during the fourth quarter. Phoenix Financial Ltd. now owns 482,724 shares of the company’s stock worth $4,552,000 after acquiring an additional 242,366 shares during the last quarter. JPMorgan Chase & Co. lifted its position in BrainsWay by 61.9% during the fourth quarter. JPMorgan Chase & Co. now owns 23,918 shares of the company’s stock worth $226,000 after acquiring an additional 9,149 shares during the last quarter. Finally, Sei Investments Co. acquired a new stake in BrainsWay during the fourth quarter worth approximately $149,000. 30.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of BrainsWay in a report on Monday, December 23rd.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.